CN109549217A - 一种以白桦茸多肽、舞茸多肽等多种成分复配制备的特膳食品 - Google Patents
一种以白桦茸多肽、舞茸多肽等多种成分复配制备的特膳食品 Download PDFInfo
- Publication number
- CN109549217A CN109549217A CN201910018100.XA CN201910018100A CN109549217A CN 109549217 A CN109549217 A CN 109549217A CN 201910018100 A CN201910018100 A CN 201910018100A CN 109549217 A CN109549217 A CN 109549217A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- pill
- inonotus obliquus
- grifola frondosa
- dietary seafood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 137
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 131
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 131
- 241000414067 Inonotus obliquus Species 0.000 title claims abstract description 39
- 240000001080 Grifola frondosa Species 0.000 title claims abstract description 32
- 235000007710 Grifola frondosa Nutrition 0.000 title claims abstract description 32
- 235000005911 diet Nutrition 0.000 title claims abstract description 28
- 230000000378 dietary effect Effects 0.000 title claims abstract description 26
- 235000014102 seafood Nutrition 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 238000013329 compounding Methods 0.000 title claims abstract description 9
- 239000006187 pill Substances 0.000 claims abstract description 29
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 22
- 239000004615 ingredient Substances 0.000 claims abstract description 19
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 claims abstract description 18
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 17
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 16
- 244000068988 Glycine max Species 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 15
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 14
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 13
- 235000013599 spices Nutrition 0.000 claims abstract description 13
- 238000001035 drying Methods 0.000 claims abstract description 12
- 230000036541 health Effects 0.000 claims abstract description 10
- 238000007789 sealing Methods 0.000 claims abstract description 10
- 238000005303 weighing Methods 0.000 claims abstract description 10
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 9
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 9
- 241000196324 Embryophyta Species 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims abstract description 8
- 230000001954 sterilising effect Effects 0.000 claims abstract description 8
- 235000013305 food Nutrition 0.000 claims abstract description 7
- 238000012216 screening Methods 0.000 claims abstract description 7
- 239000005030 aluminium foil Substances 0.000 claims abstract description 6
- 240000008620 Fagopyrum esculentum Species 0.000 claims abstract 4
- 244000078912 Trichosanthes cucumerina Species 0.000 claims abstract 4
- 239000000463 material Substances 0.000 claims description 13
- 238000012856 packing Methods 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 239000004594 Masterbatch (MB) Substances 0.000 claims description 4
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 4
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 4
- 235000021307 Triticum Nutrition 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 238000009924 canning Methods 0.000 claims description 2
- 238000010348 incorporation Methods 0.000 claims description 2
- 239000005022 packaging material Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 239000003643 water by type Substances 0.000 claims description 2
- 239000001387 apium graveolens Substances 0.000 claims 2
- 244000098338 Triticum aestivum Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 44
- 210000004369 blood Anatomy 0.000 abstract description 41
- 239000008280 blood Substances 0.000 abstract description 41
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 20
- 239000008103 glucose Substances 0.000 abstract description 20
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 17
- 206010028980 Neoplasm Diseases 0.000 abstract description 16
- 208000007882 Gastritis Diseases 0.000 abstract description 12
- 210000002784 stomach Anatomy 0.000 abstract description 9
- 208000000718 duodenal ulcer Diseases 0.000 abstract description 8
- 206010020772 Hypertension Diseases 0.000 abstract description 7
- 208000007107 Stomach Ulcer Diseases 0.000 abstract description 7
- 230000003712 anti-aging effect Effects 0.000 abstract description 7
- 201000005917 gastric ulcer Diseases 0.000 abstract description 7
- 150000002632 lipids Chemical class 0.000 abstract description 7
- 230000001093 anti-cancer Effects 0.000 abstract description 6
- 230000036772 blood pressure Effects 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 6
- 208000004930 Fatty Liver Diseases 0.000 abstract description 5
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 5
- 208000010706 fatty liver disease Diseases 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 abstract description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 5
- 230000001154 acute effect Effects 0.000 abstract description 4
- 230000000840 anti-viral effect Effects 0.000 abstract description 4
- 208000023652 chronic gastritis Diseases 0.000 abstract description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 abstract description 2
- 239000011669 selenium Substances 0.000 description 24
- 244000302512 Momordica charantia Species 0.000 description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 15
- 229910052711 selenium Inorganic materials 0.000 description 15
- 229940091258 selenium supplement Drugs 0.000 description 15
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 241000219051 Fagopyrum Species 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- 241000233866 Fungi Species 0.000 description 8
- 208000017667 Chronic Disease Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 229920001503 Glucan Polymers 0.000 description 6
- 229920002527 Glycogen Polymers 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 229940096919 glycogen Drugs 0.000 description 6
- 230000002218 hypoglycaemic effect Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 230000000975 bioactive effect Effects 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 4
- 235000018365 Momordica dioica Nutrition 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 238000009098 adjuvant therapy Methods 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- -1 lanosterol triterpenes Chemical class 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 201000001275 rectum cancer Diseases 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 241000222684 Grifola Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 208000019065 cervical carcinoma Diseases 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000019710 soybean protein Nutrition 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 235000009109 Betula pendula Nutrition 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 244000248557 Ophiopogon japonicus Species 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000001662 opsonic effect Effects 0.000 description 2
- 208000020717 oral cavity carcinoma Diseases 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-LKPKBOIGSA-N 1D-chiro-inositol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-LKPKBOIGSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 244000274847 Betula papyrifera Species 0.000 description 1
- 235000009113 Betula papyrifera Nutrition 0.000 description 1
- 241000219430 Betula pendula Species 0.000 description 1
- 235000010928 Betula populifolia Nutrition 0.000 description 1
- 235000002992 Betula pubescens Nutrition 0.000 description 1
- FZQLIPAIBVILEA-UHFFFAOYSA-N C(CCC)NC(=O)N.[S] Chemical compound C(CCC)NC(=O)N.[S] FZQLIPAIBVILEA-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 244000130270 Fagopyrum tataricum Species 0.000 description 1
- 235000014693 Fagopyrum tataricum Nutrition 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 208000019926 Keshan disease Diseases 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 229930195210 Ophiopogon Natural products 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039921 Selenium deficiency Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000003130 cardiopathic effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 150000008131 glucosides Chemical group 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037111 immune power Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000021485 packed food Nutrition 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
一种以白桦茸多肽、舞茸多肽等多种成分复配制备的特膳食品，属于食品技术领域，该特膳食品以白桦茸多肽、舞茸多肽、苦瓜多肽、苦荞多肽、黄精多肽、肉桂多肽、大豆低聚肽、麦冬、当归、富硒酵母、低聚木糖等11种多肽提取物及植物草本为配料，经原料称量、配料、混合、拌料、制丸、筛选、干燥、灭菌制得丸剂，经称量包装、PE瓶口铝箔封口、旋盖、装盒、装箱封口等工艺制成。本发明配料科学、食疗功效好，具有辅助调节血糖、血脂、血压、抗癌症，辅助治疗急慢性胃炎、胃溃疡、十二指肠溃疡、脂肪肝及糖尿病、抗病毒、抗衰老和增强免疫力等作用，是糖尿病、高血脂、高血压、胃病及肿瘤等各种慢性病患者及亚健康人士理想的食疗特膳食品。
Description
技术领域
本发明属于保健食品技术领域，特别是涉及一种以白桦茸多肽、舞茸多肽等多种成分复配制备的特膳食品。
背景技术
白桦茸多肽，是以白桦树上生长的药用真菌为原料，采用生物技术提取是一种高活性、小分子、全吸收物质。包含多种活性物质如羊毛甾醇三萜类、桦褐孔菌醇、桦褐孔菌素、多糖、木质素、生物碱、栓菌酸和黑色素等。白桦茸多肽被应用于各种疑难杂症,经大量药理实验表明其白桦茸多肽具有抗氧化、调节血脂、抗癌症(肝癌、胃癌、肺癌、宫颈癌、乳腺癌、直肠癌)、治疗糖尿病、抗病毒、抗衰老和增强免疫力等作用。
抗癌作用：采用MTT法检测白桦茸多肽对Jurkat和Daudi细胞增殖的影响,建立Jurkat荷瘤裸鼠模型,研究给药后对荷瘤裸鼠的抗肿瘤作用。表明白桦茸多肽在体外具有直接杀死Jurkat和Daudi肿瘤细胞的作用,最高抑制率分别为62.29%和66.42%,具有良好的剂量-效应关系,同时具有显著的体内抗肿瘤活性,大小剂量对Jurkat荷瘤的抑制率分别为43.52%和57.48%,并且能显著提高裸鼠的脾脏指数,具有显著的抗肿瘤活性和增强免疫功能。
护肝作用：通过白桦茸多肽作用在荷瘤鼠身上，发现白桦茸多肽(IOPS)对正常肝细胞LO2细胞无明显抑制作用，白桦茸多肽(IOPS)可明显改善荷瘤鼠肝细胞的变形坏死,具有显著的保肝作用。
降血糖作用：实验表明白桦茸多肽有效缓解糖尿病小鼠体重下降、血糖升高的症状,提高小鼠血浆胰岛素、丙酮酸激酶活性,促进葡萄糖的吸收,加速糖代谢。白桦茸多肽能够显著提高小鼠肝脏、肌肉糖原合成,抑制糖原降解,增加组织糖原含量,借此推断白桦茸多肽可能是通过影响体内葡萄糖吸收、摄取、代谢、降解等过程,抑制糖原代谢,加速糖原合成,同时增加外周组织糖消耗,达到降低小鼠血糖的目的。
抗氧化作用：利用FRAP、DPPH·、ABTS+·三种方法测定其抗氧化活性。实验表明白桦茸黄酮类化合物浓度为200μg/m L时,其总抗氧化能力相当于464.53μmol/L Fe SO4。对DPPH自由基清除率的EC50为36.44μg/m L;对ABTS+自由基清除率的EC50为299.89μg/m L。桦褐孔菌中黄酮类化合物对DPPH·和ABTS+·的清除率接近维生素C（VC）,具有较强的抗氧化活性,有潜力作为天然抗氧化剂推广应用。
调节免疫力作用：研究发现，白桦茸的水提取液可使LDH、HBDH、MDH、GCT的活性降低,过氧化氢酶的活性增强,可清除体内的自由基,保护细胞、延长传代细胞的分裂代数,增进细胞寿命,促进代谢,因而能有效地延缓衰老,长期服用可延年益寿。
日本有关报道指出,白桦茸多肽对呕吐、腹泻、胃肠功能紊乱、胃及十二指肠溃疡、肝炎、胃炎和肾炎有一定的治疗作用。对因不合理的饮食而导致的骨质方面的疾病有一定的预防和治疗作用。白桦茸多肽还可防治高血压,而且是血液的清洁剂和疼痛的缓解剂,对皮肤过敏也有一定的疗效。
舞菇多肽，舞茸在我国称之为灰树花，是一种食药兼用蕈菌。舞茸多肽是以蕈菌为原料，采用生物技术提取是一种高活性、小分子、全吸收物质。美国国家癌症研究院早在1992年就已证实，舞茸的萃取物有抵抗艾滋病病毒的功效。日本的难波宏彰博士除在实验中发现舞茸具有抗HIV的作用外，还发现对乳腺癌、肺癌、肝癌也有疗效；还可改善肿瘤的化学疗法带来的种种不良反应，如缺乏食欲、呕吐、恶心、头发脱落以及白细胞减少等等；还可缓解疼痛。此外，研究还证实灰树花同时具有以下几种功效：(1)减少胰岛素抵抗，增强人体对胰岛素的敏感度，有助于控制血糖；(2)抑制脂肪细胞堆积；(3)降低血压；(4)增强免疫力。舞茸中含有以β-（1-6）结合为主链β-（1-3）结合为侧链的葡聚糖和以β-（1-3）结合为主链β-（1-6）结合为侧链的活性葡聚糖，实验证明这些活性葡聚糖可通过活化免疫功能而显著抑制肿瘤的生长；同时还发现纯化的活性葡聚糖只有通过注射才能显效，而舞茸D-fraction（活性葡聚糖和蛋白的结合物）通过口服便可得到理想的效果。舞茸D-fraction无论是化学结构和组成成分或是分子量都有别于从香菇、云芝、灵芝、等其他菇类提取的同类物质，其生物活性也是这些同类物质所无法比拟的。
经美国、日本众多临床实验研究发现，舞茸（即灰树花）提取物--D-fration可有效激活人体免疫细胞，如NK细胞，抗毒T细胞，吞噬细胞等，从而可以达到抑制肿瘤细胞生长，诱导癌细胞凋亡的功效。此外，另外一种提取物--sx-fraction可有效控制人体血糖，修复胰岛，为众多I型和II型糖尿病患者带来福音 [2]。
舞茸多肽具有极高的医疗保健功能。据文献报导，它有抑制高血压和肥胖症的功效；由于富含铁、铜和维他命C，它能预防贫血、坏血病、白癜风，防止动脉硬化和脑血栓的发生；它的硒和铬含量较高，有保护肝脏、胰脏，预防肝硬化和糖尿病的作用；硒含量高使其还具有防治克山病、大骨节病和某些心脏病的功能；它兼含钙和维生素D，两者配合，能有效地防治佝偻病；较高的锌含量有利大脑发育、保持视觉敏锐，促进伤口愈合；高含量的维生素E和硒配合，使之能抗衰老、增强记忆力和灵敏度。
苦瓜多肽，系苦瓜中提取的生物活性物质,被誉为天然胰岛素，具有明显降糖作用。 印度医学科学家发现苦瓜中多肽-P,其作用比降糖药“申磺丁脲”还强;据印度的罕娜博士报告，从苦瓜中提取的一种多肽药物用于治疗糖尿病，结果与胰岛素同样有效。 苦瓜多肽生物活性成分由17种166个氨基酸组成，与胰岛素有相似的结构和理化指标，具有显著的调节血糖效果。国内外医院的临床实验证明证实，苦瓜多肽在进入人体30分钟后起效，其降低血糖的持续时间为4—8小时，特别是在控制餐后血糖的效果更为突出。同时，苦瓜多肽降低血糖的作用效果持久，并不会发生低血糖。苦瓜多肽是一种纯天然植物成分，通过激活胰岛素、激活胰岛素受体，提高胰岛素有效利用率来调节血糖，从而，实现了血糖按照人体正常生理自然规律表达的目的，且没有副作用。苦瓜多肽为糖尿病患者及血糖偏高人群提供了一种安全，持久的血糖调节的解决方案，缓解了人们在使用药物调节血糖时，给自身带来的一系列身心损害的难题，因此，苦瓜多肽特别适用各类的糖尿病患者及糖尿病的高危人群。
苦荞多肽系苦荞麦中提取的生物活性物质，其中，苦荞糖醇可在人体肠道微生物的作用下降解 D—手性肌醇，提高胰岛素的敏感性，从而降低动物和人体的血糖、血脂水平。2，4—二羟基顺式肉桂酸：含有抑制皮肤生成黑色素物质，可预防老年斑和雀斑。蛋白质阻碍酶，有阻碍白血病细胞的增殖作用。抗（慢）消化淀粉有阻止血糖快升和减肥的作用。
黄精多肽，系黄精中提取的生物活性物质。能够抑制肝糖元分解，减少血糖的来源。可以刺激胰岛细胞分泌胰岛素以达到降血糖的效果。同时，黄精多肽在治疗肾虚作用非常明显，能够活化男性中枢神经，疏通人体血管。正是这些特点，让黄精多肽远远领先其他同类中药材产品，获 "补肾黄金"称号。黄精多肽不仅能补脾阴，又益脾气，对于脾胃气虚而倦怠乏力，食欲不振等具有非常好的调理作用。
肉桂多肽，系肉桂中提取的生物活性物质，药理研究显示，肉桂多肽对于胰岛素的功能具有改善作用，可以帮助转运葡萄糖，进而达到降低体内血糖水平的作用，此外，肉桂多肽对于收缩压还具有一定的降低作用，因而具有降压降糖作用，由此也适宜糖尿病人群使用。
大豆低聚肽，是运用蛋白质工程的分离技术，将中国传统大豆(非转基因大豆和改良大豆)，蛋白质分离，将大豆蛋白分离成蛋白质含量在90%以上的大豆分离蛋白，再用生物工程的酶催化技术将大豆分离蛋白催化成分子量在500—175之间。大豆多肽具有易消化吸收性。人工合成已在体外解决了它的消化问题，它进入人体不需消化，直接吸收；可促进能量代谢，从而显现出抗肥胖作用；可促过度疲劳恢复精神、体力的效果；并能降低胆固醇，调节血液粘稠度，改善血管通透性，防止动脉血管粥样硬化，防止脑血栓，防止中风；调节胰岛素分泌，从而达到降低血糖的作用。
麦冬（Ophiopogon japonicus）百合科沿阶草属多年生常绿草本植物。味甘微苦，微寒。具有润肺清心、泻热生津、化痰止呕、治嗽行水之作用。我国古代《神农本草经》记载麦冬为养阴润肺的上品，言其“久服轻身，不老不饥”。《医学衷中参西录》言其：“能入胃以养胃液，开胃进食，更能入脾以助脾散精于肺，定喘宁嗽。”中医认为，麦冬味甘、微苦，性微寒，归胃、肺、心经，有养阴润肺、益胃生津、清心除烦的功效，用于肺燥干咳、阴虚痨嗽、喉痹咽痛、津伤口渴、内热消渴、心烦失眠、肠燥便秘等症。现代药理研究也表明，麦冬具有抗疲劳、清除自由基、提高细胞免疫功能以及降血糖、促进胰岛细胞功能恢复、增加肝糖原的作用。此外，麦冬有镇静、催眠、抗心肌缺血、抗心律失常、抗肿瘤等作用，尤其对增进老年人健康具有多方面功效。
当归（Angelica sinensis）属多生草本，其根可以入药。具有补血和血、调经止痛、润燥滑肠、抗癌 、抗老防老 、增强免疫等健康作用。当归味甘而重，故专能补血，其气轻而辛，故又能行血，补中有动，行中有补，为血中之要药。适用于心肝血虚证所致的面色苍白或萎黄、倦怠乏力、唇甲浅淡无华、头晕目眩、心悸失眠等症。另外，当归也是抗肿瘤良药，可广泛用于各种肿瘤，尤其是妇科肿瘤，以气血停滞、瘀血凝聚者最宜。对血虚羸瘦的中晚期癌症或手术、放疗、化疗后正气虚弱之患者，亦可选用当归，以扶正抗癌。
富硒酵母（Selenium enriched yeast）就是在培养酵母的过程中加入硒元素，酵母生长时吸收利用了硒，使硒与酵母体内的蛋白质和多糖有机结合转化为生物硒，从而消除了化学硒（如亚硒酸钠）对人体的毒副反应和肠胃刺激，使硒能够更高效、更安全地被人体吸收利用。富硒酵母也是迄今为止国内最高效、最安全、营养最均衡的补硒制剂。硒也是人体所必需的微量元素，有很重要的生理功能，与人类的健康密切相关。硒能够预防和抑制肿瘤、抗衰老、维持心血管系统的正常功能，预防动脉硬化和冠心病的出现。缺硒会导致克山病和大骨结病，还会诱发白内障、肝病和胰腺病等。现代医学研究证明，补硒可降低肝癌、胃癌、肺癌、前列腺癌和直肠癌的发病率，同时，硒能刺激免疫球蛋白的产生，使人体的各种免疫功能如：细胞免疫、体液免疫、非特异性等得到改善。研究发现，糖尿病人血硒明显低于正常人的血硒，补硒能够降低血糖、增加GPX的活性、能刺激脂肪细胞膜上的葡聚糖载体的转运过程。
低聚木糖（xylooligosaccharide）又称木寡糖，是由2-7个木糖分子以β-1,4糖苷键结合而成的功能性聚合糖。与通常人们所用的大豆低聚糖、低聚果糖、低聚异麦芽糖等相比具有独特的优势，它可以选择性地促进肠道双歧杆菌的增殖活性。其双歧因子功能是其它聚合糖类的10-20倍。在防治便秘方面，双歧杆菌利用低聚木糖，产生大量的短链脂肪酸；能刺激肠道蠕动，增加粪便湿润度，并保持一定的渗透压，从而防止便秘发生。 同时，低聚木糖可减少有毒代谢产物形成，大大减少了肝脏分解毒素的负担，还具体降低血清胆固醇、降低血压等诸多健康作用。
随着中国经济的快速发展，人民生活水平的不断提高，人们在享受大鱼大肉美味的同时，也不知不自觉的给身体带来了负担。于是亚健康人群越来越多，我国也逐渐成为一个慢性病大国。据国家卫生计生委疾控局数据显示，中国慢性病确诊患者已接近3亿人，心脑血管疾病超过2亿人；全国超过1.25亿的肥胖症患者， 1.6亿人患高血压，每年增加1000万人；糖尿病患者9240万人。
目前，慢性病导致的死亡率已经占到我国人口总死亡率的85%，导致的疾病负担已占总疾病负担的70%，中国正进入慢性病的高发期。因此，市场急需一种能够调理高血糖、高血脂、高血压、脂肪肝、肥胖，以及辅助肿瘤、胃炎、胃溃疡、十二指肠溃疡等慢性病调理的特膳食品。
发明内容
本发明的目的是针对高血糖、高血脂、高血压、脂肪肝，以及肿瘤、胃炎、胃溃疡、十二指肠溃疡等慢性病人群的健康状况。结合目前市场上药用真菌及植物草本产品配方单一，原料纯度不高、真菌活性成分较低、患者食疗效果差等不足之处，提供一种采用白桦茸多肽、舞茸多肽、苦瓜多肽等多种多肽原料，经科学配伍而成，具有辅助降血糖、降血脂、降血压、减肥，辅助治疗急慢性胃炎、胃溃疡、十二指肠溃疡、肿瘤等慢性病调理作用的特膳食品。
本发明的技术方案是这样的：
一种以白桦茸多肽、舞茸多肽等多种成分复配制备的特膳食品。该特膳食品包括白桦茸多肽、舞茸多肽、苦瓜多肽、苦荞多肽、黄精多肽、肉桂多肽、大豆低聚肽、麦冬、当归、富硒酵母、低聚木糖等11种多肽提取物及植物草本为配料，经原料称量、配比、混合、拌料、制丸、筛选、干燥、灭菌、包装等生产工艺制成的一种华肽豆食疗特膳食品。
所述的特膳食品产品配料每100g中含有：白桦茸多肽16g-13g、舞茸多肽16g-13g、苦瓜多肽15g-12g、苦荞多肽11g-9g、大豆低聚肽11g-9g、黄精多肽7-5g、肉桂多肽7g-5g、麦冬6g-5g、当归6g-5g、富硒酵母6-5g、低聚木糖6g-5g。
一种以白桦茸多肽、舞茸多肽等多种成分复配特膳食品制备方法如下：
将白桦茸多肽、舞茸多肽、苦瓜多肽、苦荞多肽、黄精多肽、肉桂多肽、大豆低聚肽、麦冬、当归、富硒酵母、低聚木糖等11种多肽提取物及植物草本原料按照比例分别进行称量、配料、混合、拌料、制丸、筛选、干燥、灭菌得到的(直径小于0.5cm)丸剂。
具体工艺流程如下：
a称量：将白桦茸多肽、舞茸多肽、苦瓜多肽、苦荞多肽、黄精多肽、肉桂多肽、大豆低聚肽、麦冬、当归、富硒酵母、低聚木糖等粉剂原料分别按比例称量备用；
b混合：将已称量的原料倒入混合机进行干混，混合时间为30分钟；
c拌料：将混合后的粉剂带入槽混机，按混合料50公斤比700毫升净化水进行湿法均衡混合拌料，以拌料手捏成团即可；
d制丸：将拌料加入制丸挤出机料斗，进行挤压、剪切母粒，将挤出机剪切母粒送螺旋式制丸机进行丸剂滚圆均制；
e干燥：将滚圆好的丸剂装盘并连同烘车一起推入干燥箱进行丸剂干燥、灭菌，干燥箱蒸汽温度60-80度，压力为0.2-0.4MPa，时间为30分钟。
f包装：采用符合卫生条件的食品级PE塑料瓶材质，设定包装机丸剂量杯重量，操作丸剂包装机灌装线、瓶口铝箔热封、旋盖至成品即可。本发明保健食品的瓶装包装规格为150g/瓶，每丸重量为1 g(直径小于0.5cm)。瓶装包材选用符合食品卫生级PE材质，包装盒材选用食品级单面白卡纸材料，外包装箱材料选用5层瓦楞纸制箱，产品包装说明符合国预包装食品标标识标签管理规定。
本发明具有如下效果：
1、本发明特膳食品原料选用以白桦茸多肽、舞茸多肽、苦瓜多肽、苦荞多肽、黄精多肽、肉桂多肽、大豆低聚肽、麦冬、当归、富硒酵母、低聚木糖等11种原料配伍而成，产品具有辅助调节血糖、血脂、抗癌症(口腔癌、食道癌、肝癌、胃癌、肺癌、宫颈癌、乳腺癌、直肠癌)、治疗急慢性胃炎、胃溃疡、十二指肠溃疡、脂肪肝及糖尿病、抗病毒、抗衰老和增强免疫力等作用。
2、本发明科学配伍11种天然真菌多肽和植物多肽及草本原料，产品具有抗氧化、抗肿瘤、激活免疫细胞、调节血糖、减少胰岛素抵抗，增强人体对胰岛素的敏感度；抑制脂肪细胞堆积；降低血压；增强免疫、止痛消炎、保护肝脏、胰脏，预防肝硬化和糖尿病等诸多作用；对呕吐、腹泻、胃肠功能紊乱、胃及十二指肠溃疡、肝炎、胃炎和肾炎有一定的辅助治疗作用。产品能够改善肿瘤的化学疗法带来的种种不良反应，如缺乏食欲、呕吐、恶心、头发脱落以及白细胞减少等等；还可缓解疼痛，是肿瘤患者放化疗理想的辅助治疗特膳食品。
3、本发明科学解决了传统产品真菌有效成分不高、真菌活性低、配料单一、配方不科学，食疗功效差、买真菌概念等技术问题。与传统真菌配方及生产工艺相比，本发明具有真菌含量活性成分高、肠胃易吸收、配料科学、功效显著、无副作用等诸多健康优点。
4、本发明产品生产流程工艺采用原料称量、配料、混合、拌料、制丸、筛选、干燥、灭菌制得(直径小于0.5cm)丸剂，经丸剂包装机称量包装、PE瓶口铝箔封口、旋盖、装盒、装箱封口等工艺制成，具有生产工艺成熟、生产设备先进、生产效率高等优点。
具体实施方式
本发明的具体实施方式参照实施例。下面对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。
本发明主要配方实施例有以下几种：
实施例1：一种以白桦茸多肽、舞茸多肽等多种成分复配制备的特膳食品，该特膳食品每100g产品配料中含有：白桦茸多肽15g、舞茸多肽15g、苦瓜多肽13g、苦荞多肽11g、大豆低聚肽12g、黄精多肽7g、肉桂多肽6g、麦冬6g、当归5g、富硒酵母5g、低聚木糖5g。
上述原料经称量、配料、混合、拌料、制丸、筛选、干燥、灭菌制得(直径小于0.5cm)丸剂，经丸剂包装机称量包装、PE瓶口铝箔封口、旋盖、装盒、装箱封口等工艺制成的一种华肽豆食疗特膳食品。
实施例2：一种以白桦茸多肽、舞茸多肽等多种成分复配制备的特膳食品，每100g产品配料中含有：白桦茸多肽14g、舞茸多肽14g、苦瓜多肽14g、苦荞多肽10、大豆低聚肽11g、黄精多肽7g、肉桂多肽6g、麦冬6g、当归6gg、富硒酵母6g、低聚木糖6g。
上述原料经称量、配料、混合、拌料、制丸、筛选、干燥、灭菌制得(直径小于0.5cm)丸剂，经丸剂包装机称量包装、PE瓶口铝箔封口、旋盖、装盒、装箱封口等工艺制成的一种华肽豆食疗特膳食品。
本发明特膳食品配料科学、食疗健康功效好，具有辅助调节血糖、血脂、血压、抗癌症(口腔癌、食道癌、肝癌、胃癌、肺癌、宫颈癌、乳腺癌、直肠癌)，辅助治疗急慢性胃炎、胃溃疡、十二指肠溃疡、脂肪肝及糖尿病、抗病毒、抗衰老和增强免疫力等作用，是糖尿病、高血脂、高血压、胃病及肿瘤等各种慢性病患者及亚健康人士理想的食疗特膳食品。
Claims (4)
1.一种以白桦茸多肽、舞茸多肽等多种成分复配制备的特膳食品，其特征在于：该保健食品包括白桦茸多肽、舞茸多肽、苦瓜多肽、苦荞多肽、黄精多肽、肉桂多肽、大豆低聚肽、麦冬、当归、富硒酵母、低聚木糖等11种多肽提取物及植物草本。
2.根据权利要求1所述的特膳食品，其特征在于该特膳食品配料每100g中含有：白桦茸多肽18g-16g、舞茸多肽18g-16g、苦瓜多肽16g-14g、苦荞多肽12g-10g、大豆低聚肽12g-10g、黄精多肽8g-6g、肉桂多肽7g-5g、麦冬6g-5g、当归6g-5g、富硒酵母6-5g、低聚木糖6g-5g。
3.根据权利要求1或2所述的特膳食品，其特征在于芹菜籽优选西芹籽为佳。
4.一种以白桦茸多肽、舞茸多肽等多种成分复配特膳食品的制备方法，其特征在于，将白桦茸多肽、舞茸多肽等11种原料分别进行称量、配料、混合、拌料、制丸、筛选、干燥、灭菌得到的(直径小于0.5cm)丸剂，具体工序为：
a称量：将白桦茸多肽、舞茸多肽、苦瓜多肽、苦荞多肽、黄精多肽、肉桂多肽、大豆低聚肽、麦冬、当归、富硒酵母、低聚木糖等粉剂原料分别称量备用；
b混合：将称量的11种原料倒入混合机进行干混，混合时间为30分钟；
c拌料：将混合后的粉剂带入槽混机，按混合料50公斤比700毫升净化水进行湿法均衡混合拌料，以拌料手捏成团即可；
d制丸：将拌料加入制丸挤出机料斗，进行挤压、剪切母粒，将挤出机剪切母粒送螺旋式制丸机进行丸剂滚圆均制；
e干燥：将滚圆好的丸剂装盘并连同烘车一起推入干燥箱进行丸剂干燥、灭菌，干燥箱蒸汽温度60-80度，压力为0.2-0.4MPa，时间为30分钟。
f包装：采用符合卫生条件的食品级PE塑料瓶材质，设定包装机丸剂量杯重量，操作丸剂包装机灌装线、瓶口铝箔热封、旋盖至成品即可。本发明华肽豆膳食品的瓶装包装规格为150g/瓶，，瓶装包材选用符合食品卫生级PE材质，包装盒材选用食品级单面白卡纸材料，外包装箱材料选用5层瓦楞纸制箱，产品包装说明符合国预包装食品标标识标签管理规定。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910018100.XA CN109549217A (zh) | 2019-01-09 | 2019-01-09 | 一种以白桦茸多肽、舞茸多肽等多种成分复配制备的特膳食品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910018100.XA CN109549217A (zh) | 2019-01-09 | 2019-01-09 | 一种以白桦茸多肽、舞茸多肽等多种成分复配制备的特膳食品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109549217A true CN109549217A (zh) | 2019-04-02 |
Family
ID=65872801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910018100.XA Pending CN109549217A (zh) | 2019-01-09 | 2019-01-09 | 一种以白桦茸多肽、舞茸多肽等多种成分复配制备的特膳食品 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109549217A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112079937A (zh) * | 2020-08-10 | 2020-12-15 | 吉林省桦树茸国际健康产业集团有限公司 | 桦树茸中降血糖多糖和多肽的提取和包合以及在饼干中的应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814167A (zh) * | 2005-12-12 | 2006-08-09 | 张恩及 | 一种用于糖尿病的保健品 |
| CN104757252A (zh) * | 2015-04-22 | 2015-07-08 | 福建农林大学 | 一种具有抗氧化活性的灰树花蛋白酶解物的制备方法 |
| DE202018101021U1 (de) * | 2017-02-24 | 2018-03-07 | Liudmila Kalitukha | Mittel zur Normalisierung von Haarwachstum und Kopfhautzustand |
| CN108606222A (zh) * | 2018-06-06 | 2018-10-02 | 唐山肽景堂生物科技有限公司 | 一种祛糖尿病肽复配的固体饮料及其制备方法 |
-
2019
- 2019-01-09 CN CN201910018100.XA patent/CN109549217A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814167A (zh) * | 2005-12-12 | 2006-08-09 | 张恩及 | 一种用于糖尿病的保健品 |
| CN104757252A (zh) * | 2015-04-22 | 2015-07-08 | 福建农林大学 | 一种具有抗氧化活性的灰树花蛋白酶解物的制备方法 |
| DE202018101021U1 (de) * | 2017-02-24 | 2018-03-07 | Liudmila Kalitukha | Mittel zur Normalisierung von Haarwachstum und Kopfhautzustand |
| CN108606222A (zh) * | 2018-06-06 | 2018-10-02 | 唐山肽景堂生物科技有限公司 | 一种祛糖尿病肽复配的固体饮料及其制备方法 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112079937A (zh) * | 2020-08-10 | 2020-12-15 | 吉林省桦树茸国际健康产业集团有限公司 | 桦树茸中降血糖多糖和多肽的提取和包合以及在饼干中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1170588A (zh) | 一种纯天然植物人体生命核能营养基质 | |
| CN104856003A (zh) | 糖尿病非全营养配方食品 | |
| CN1742927A (zh) | 枸杞桑椹片及其制备工艺 | |
| CN104147132A (zh) | 能够降低血糖调节胰岛素分泌的软胶囊及制作方法 | |
| CN109550040A (zh) | 一种增强免疫力的中药多肽组合物 | |
| CN104479946A (zh) | 黄秋葵、菌、藻植物组合物制作营养露酒的方法 | |
| CN105533688A (zh) | 一种辅助降血糖保健软胶囊及其制备方法 | |
| CN110327421A (zh) | 一种适合宇航员具有提高精力和协调人体各器官功能的组合物 | |
| CN106343567A (zh) | 一种诺丽果口服液及其制备方法 | |
| CN104855968A (zh) | 肝癌非全营养配方食品 | |
| CN104473286A (zh) | 黄秋葵、菌、藻合成的固体(功能)饮料及其制备方法 | |
| CN104479964A (zh) | 一种黄秋葵、菌、藻保健酒及其制备方法 | |
| CN109549217A (zh) | 一种以白桦茸多肽、舞茸多肽等多种成分复配制备的特膳食品 | |
| CN103340919B (zh) | 一种灵芝精粉复方软胶囊及其制备方法 | |
| CN110638038A (zh) | 一种用于控制高血糖的医学配方营养代餐粉及其制备方法 | |
| CN109527577A (zh) | 一种具有解酒护肝功能的组合物 | |
| CN104856008A (zh) | 萎缩性胃炎非全营养配方食品 | |
| CN104825817B (zh) | 一种具有抗肿瘤作用的中药制剂 | |
| CN102861236A (zh) | 一种纯中药抗肿瘤制剂 | |
| CN106138900A (zh) | 辅助治疗高血糖和糖尿病并发症的组合物及其应用 | |
| CN104855971A (zh) | 骨瘤非全营养配方食品 | |
| CN104382007B (zh) | 一种功能性胶囊及其制备方法 | |
| CN104432305A (zh) | 一种食疗功能饮料及其制备方法 | |
| CN110089754A (zh) | 肝胆保健品 | |
| CN109998021A (zh) | 健脾胃、抗动脉硬化、降三高、补钙养颜的面粉 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190402 |
|
| WD01 | Invention patent application deemed withdrawn after publication |